CAR T-Cell Therapy May Help Mitigate Disparities in Pediatric ALL
Children from historically marginalized populations who have been diagnosed with acute lymphoblastic leukemia (ALL) relapse and die more often than those from advantaged households...
Real-World Data Support Licensed Use of Tisagenlecleucel in Infants, Young Children With B-Cell ALL
The safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy with tisagenlecleucel in infants and children younger than 3 with relapsed or refractory B-cell acute lymphoblastic leukemia...
Inhibition of Mutant IDH1 Stimulates AML Stem Cell Cycling
Around 20% of patients with AML carry mutations in IDH1 or IDH2, resulting in over-production of the oncometabolite D-2-hydroxyglutarate ...
AML Framework IDs 16 Subgroups, 3 Risk Strata
Researchers used comprehensive molecular profiling data to develop a new classification and risk-stratification system for acute myeloid leukemia...
Population-Based Score Gauges Risk of Early Death in APL
Current treatments have cure rates at about 90%, and the most serious obstacle for patients is early death from a coagulopathy that results in hemorrhage and thrombosis ...
Venetoclax Proves Active in Newly Diagnosed AML
Two studies investigating the activity and safety of the BCL-2 inhibitor venetoclax support its use as part of first-line treatment in adults with newly diagnosed acute myeloid leukemia (AML)....
AlloHCT Outcomes Improved in Adults With ALL
Outcomes for allogeneic hematopoietic cell transplantation (alloHCT) for acute lymphoblastic leukemia (ALL) have improved in the past 30 years, according to study findings published in Blood Advances....
Ivosidenib/Azacitidine Combo Improved Overall Survival in IDH1-Mutated AML
The combination of the IDH1 inhibitor ivosidenib and azacitidine demonstrated significant clinical benefit in patients with newly diagnosed IDH1-mutated acute myeloid leukemia...
Code Status Transition in High-Risk AML Happening Near End of Life
Patients with high-risk acute myeloid leukemia (AML) often had code change status transitions occur very near the end of life...
Azacitidine and Decitabine Garner Comparable Clinical Outcomes Among Older, Unfit Patients With AML
Treatment responses and survival outcomes were comparable among older, unfit patients with acute myeloid leukemia (AML) who received either of two hypomethylating agents (HMAs), azacitidine or decitabine...
